Long-term efficacy and safety of thalamic stimulation for drug-resistant partial epilepsy

Vicenta Salanova, Thomas Witt, Robert Worth, Thomas R. Henry, Robert E. Gross, Jules M. Nazzaro, Douglas Labar, Michael R. Sperling, Ashwini Sharan, Evan Sandok, Adrian Handforth, John M. Stern, Steve Chung, Jaimie M. Henderson, Jacqueline French, Gordon Baltuch, William E. Rosenfeld, Paul Garcia, Nicholas Barbaro, Nathan B. FountainW. Jeffrey Elias, Robert R. Goodman, John R. Pollard, Alexander I. Tröster, Christopher P. Irwin, Kristin Lambrecht, Nina Graves, Robert Fisher

Research output: Contribution to journalArticle

217 Citations (Scopus)

Abstract

Objective: To report long-term efficacy and safety results of the SANTE trial investigating deep brain stimulation of the anterior nucleus of the thalamus (ANT) for treatment of localization-related epilepsy. Methods: This long-term follow-up is a continuation of a previously reported trial of 5-vs 0-V ANT stimulation. Long-term follow-up began 13 months after device implantation with stimulation parameters adjusted at the investigators' discretion. Seizure frequency was determined using daily seizure diaries. Results: The median percent seizure reduction from baseline at 1 year was 41%, and 69% at 5 years. The responder rate (≥50% reduction in seizure frequency) at 1 year was 43%, and 68% at 5 years. In the 5 years of follow-up, 16% of subjects were seizure-free for at least 6 months. There were no reported unanticipated adverse device effects or symptomatic intracranial hemorrhages. The Liverpool Seizure Severity Scale and 31-item Quality of Life in Epilepsy measure showed statistically significant improvement over baseline by 1 year and at 5 years (p < 0.001). Conclusion: Long-term follow-up of ANT deep brain stimulation showed sustained efficacy and safety in a treatment-resistant population. Classification of evidence: This long-term follow-up provides Class IV evidence that for patients with drug-resistant partial epilepsy, anterior thalamic stimulation is associated with a 69% reduction in seizure frequency and a 34% serious device-related adverse event rate at 5 years.

Original languageEnglish
Pages (from-to)1017-1025
Number of pages9
JournalNeurology
Volume84
Issue number10
DOIs
StatePublished - Mar 10 2015

Fingerprint

Partial Epilepsy
Seizures
Safety
Anterior Thalamic Nuclei
Deep Brain Stimulation
Equipment and Supplies
Intracranial Hemorrhages
Drug Resistant Epilepsy
Epilepsy
Quality of Life
Research Personnel
Therapeutics
Population

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Salanova, V., Witt, T., Worth, R., Henry, T. R., Gross, R. E., Nazzaro, J. M., ... Fisher, R. (2015). Long-term efficacy and safety of thalamic stimulation for drug-resistant partial epilepsy. Neurology, 84(10), 1017-1025. https://doi.org/10.1212/WNL.0000000000001334

Long-term efficacy and safety of thalamic stimulation for drug-resistant partial epilepsy. / Salanova, Vicenta; Witt, Thomas; Worth, Robert; Henry, Thomas R.; Gross, Robert E.; Nazzaro, Jules M.; Labar, Douglas; Sperling, Michael R.; Sharan, Ashwini; Sandok, Evan; Handforth, Adrian; Stern, John M.; Chung, Steve; Henderson, Jaimie M.; French, Jacqueline; Baltuch, Gordon; Rosenfeld, William E.; Garcia, Paul; Barbaro, Nicholas; Fountain, Nathan B.; Elias, W. Jeffrey; Goodman, Robert R.; Pollard, John R.; Tröster, Alexander I.; Irwin, Christopher P.; Lambrecht, Kristin; Graves, Nina; Fisher, Robert.

In: Neurology, Vol. 84, No. 10, 10.03.2015, p. 1017-1025.

Research output: Contribution to journalArticle

Salanova, V, Witt, T, Worth, R, Henry, TR, Gross, RE, Nazzaro, JM, Labar, D, Sperling, MR, Sharan, A, Sandok, E, Handforth, A, Stern, JM, Chung, S, Henderson, JM, French, J, Baltuch, G, Rosenfeld, WE, Garcia, P, Barbaro, N, Fountain, NB, Elias, WJ, Goodman, RR, Pollard, JR, Tröster, AI, Irwin, CP, Lambrecht, K, Graves, N & Fisher, R 2015, 'Long-term efficacy and safety of thalamic stimulation for drug-resistant partial epilepsy', Neurology, vol. 84, no. 10, pp. 1017-1025. https://doi.org/10.1212/WNL.0000000000001334
Salanova, Vicenta ; Witt, Thomas ; Worth, Robert ; Henry, Thomas R. ; Gross, Robert E. ; Nazzaro, Jules M. ; Labar, Douglas ; Sperling, Michael R. ; Sharan, Ashwini ; Sandok, Evan ; Handforth, Adrian ; Stern, John M. ; Chung, Steve ; Henderson, Jaimie M. ; French, Jacqueline ; Baltuch, Gordon ; Rosenfeld, William E. ; Garcia, Paul ; Barbaro, Nicholas ; Fountain, Nathan B. ; Elias, W. Jeffrey ; Goodman, Robert R. ; Pollard, John R. ; Tröster, Alexander I. ; Irwin, Christopher P. ; Lambrecht, Kristin ; Graves, Nina ; Fisher, Robert. / Long-term efficacy and safety of thalamic stimulation for drug-resistant partial epilepsy. In: Neurology. 2015 ; Vol. 84, No. 10. pp. 1017-1025.
@article{971f92f3cf204ef1a27613bb0a6d6c66,
title = "Long-term efficacy and safety of thalamic stimulation for drug-resistant partial epilepsy",
abstract = "Objective: To report long-term efficacy and safety results of the SANTE trial investigating deep brain stimulation of the anterior nucleus of the thalamus (ANT) for treatment of localization-related epilepsy. Methods: This long-term follow-up is a continuation of a previously reported trial of 5-vs 0-V ANT stimulation. Long-term follow-up began 13 months after device implantation with stimulation parameters adjusted at the investigators' discretion. Seizure frequency was determined using daily seizure diaries. Results: The median percent seizure reduction from baseline at 1 year was 41{\%}, and 69{\%} at 5 years. The responder rate (≥50{\%} reduction in seizure frequency) at 1 year was 43{\%}, and 68{\%} at 5 years. In the 5 years of follow-up, 16{\%} of subjects were seizure-free for at least 6 months. There were no reported unanticipated adverse device effects or symptomatic intracranial hemorrhages. The Liverpool Seizure Severity Scale and 31-item Quality of Life in Epilepsy measure showed statistically significant improvement over baseline by 1 year and at 5 years (p < 0.001). Conclusion: Long-term follow-up of ANT deep brain stimulation showed sustained efficacy and safety in a treatment-resistant population. Classification of evidence: This long-term follow-up provides Class IV evidence that for patients with drug-resistant partial epilepsy, anterior thalamic stimulation is associated with a 69{\%} reduction in seizure frequency and a 34{\%} serious device-related adverse event rate at 5 years.",
author = "Vicenta Salanova and Thomas Witt and Robert Worth and Henry, {Thomas R.} and Gross, {Robert E.} and Nazzaro, {Jules M.} and Douglas Labar and Sperling, {Michael R.} and Ashwini Sharan and Evan Sandok and Adrian Handforth and Stern, {John M.} and Steve Chung and Henderson, {Jaimie M.} and Jacqueline French and Gordon Baltuch and Rosenfeld, {William E.} and Paul Garcia and Nicholas Barbaro and Fountain, {Nathan B.} and Elias, {W. Jeffrey} and Goodman, {Robert R.} and Pollard, {John R.} and Tr{\"o}ster, {Alexander I.} and Irwin, {Christopher P.} and Kristin Lambrecht and Nina Graves and Robert Fisher",
year = "2015",
month = "3",
day = "10",
doi = "10.1212/WNL.0000000000001334",
language = "English",
volume = "84",
pages = "1017--1025",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Long-term efficacy and safety of thalamic stimulation for drug-resistant partial epilepsy

AU - Salanova, Vicenta

AU - Witt, Thomas

AU - Worth, Robert

AU - Henry, Thomas R.

AU - Gross, Robert E.

AU - Nazzaro, Jules M.

AU - Labar, Douglas

AU - Sperling, Michael R.

AU - Sharan, Ashwini

AU - Sandok, Evan

AU - Handforth, Adrian

AU - Stern, John M.

AU - Chung, Steve

AU - Henderson, Jaimie M.

AU - French, Jacqueline

AU - Baltuch, Gordon

AU - Rosenfeld, William E.

AU - Garcia, Paul

AU - Barbaro, Nicholas

AU - Fountain, Nathan B.

AU - Elias, W. Jeffrey

AU - Goodman, Robert R.

AU - Pollard, John R.

AU - Tröster, Alexander I.

AU - Irwin, Christopher P.

AU - Lambrecht, Kristin

AU - Graves, Nina

AU - Fisher, Robert

PY - 2015/3/10

Y1 - 2015/3/10

N2 - Objective: To report long-term efficacy and safety results of the SANTE trial investigating deep brain stimulation of the anterior nucleus of the thalamus (ANT) for treatment of localization-related epilepsy. Methods: This long-term follow-up is a continuation of a previously reported trial of 5-vs 0-V ANT stimulation. Long-term follow-up began 13 months after device implantation with stimulation parameters adjusted at the investigators' discretion. Seizure frequency was determined using daily seizure diaries. Results: The median percent seizure reduction from baseline at 1 year was 41%, and 69% at 5 years. The responder rate (≥50% reduction in seizure frequency) at 1 year was 43%, and 68% at 5 years. In the 5 years of follow-up, 16% of subjects were seizure-free for at least 6 months. There were no reported unanticipated adverse device effects or symptomatic intracranial hemorrhages. The Liverpool Seizure Severity Scale and 31-item Quality of Life in Epilepsy measure showed statistically significant improvement over baseline by 1 year and at 5 years (p < 0.001). Conclusion: Long-term follow-up of ANT deep brain stimulation showed sustained efficacy and safety in a treatment-resistant population. Classification of evidence: This long-term follow-up provides Class IV evidence that for patients with drug-resistant partial epilepsy, anterior thalamic stimulation is associated with a 69% reduction in seizure frequency and a 34% serious device-related adverse event rate at 5 years.

AB - Objective: To report long-term efficacy and safety results of the SANTE trial investigating deep brain stimulation of the anterior nucleus of the thalamus (ANT) for treatment of localization-related epilepsy. Methods: This long-term follow-up is a continuation of a previously reported trial of 5-vs 0-V ANT stimulation. Long-term follow-up began 13 months after device implantation with stimulation parameters adjusted at the investigators' discretion. Seizure frequency was determined using daily seizure diaries. Results: The median percent seizure reduction from baseline at 1 year was 41%, and 69% at 5 years. The responder rate (≥50% reduction in seizure frequency) at 1 year was 43%, and 68% at 5 years. In the 5 years of follow-up, 16% of subjects were seizure-free for at least 6 months. There were no reported unanticipated adverse device effects or symptomatic intracranial hemorrhages. The Liverpool Seizure Severity Scale and 31-item Quality of Life in Epilepsy measure showed statistically significant improvement over baseline by 1 year and at 5 years (p < 0.001). Conclusion: Long-term follow-up of ANT deep brain stimulation showed sustained efficacy and safety in a treatment-resistant population. Classification of evidence: This long-term follow-up provides Class IV evidence that for patients with drug-resistant partial epilepsy, anterior thalamic stimulation is associated with a 69% reduction in seizure frequency and a 34% serious device-related adverse event rate at 5 years.

UR - http://www.scopus.com/inward/record.url?scp=84924386542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924386542&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000001334

DO - 10.1212/WNL.0000000000001334

M3 - Article

C2 - 25663221

AN - SCOPUS:84924386542

VL - 84

SP - 1017

EP - 1025

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 10

ER -